Stephan van Gerven, CEO
For many millennia, Cannabis—also known as marijuana—has been looked upon for its therapeutic potential by different cultures around the world. Its most primitive evidential medical use dates back to as early as 2700 BC.
While the most common use for medical marijuana is pain control, it has been quite effective for treating glaucoma and managing weight loss. Another highly promising area of research is its use for post-traumatic stress disorder (PTSD) in veterans who are returning from combat zones.
But what makes this herb such a miraculous healer?
CBD (cannabidiol) and THC (tetrahydrocannabinol), the two main components found in cannabis, are the main reasons behind its huge medicinal value for both physical and mental health. According to recent studies, both CBD and THC bind to different neuroreceptors and confer different therapeutic benefits. Today, there are, in fact, various ongoing studies that aim to showcase Cannabis’ potential in fighting COVID-19, thanks largely to its anti-inflammatory properties.
However, as many scientists and doctors would acknowledge, the medicinal effect of cannabis depend largely on their strains and the purity of the product. And not every strain of cannabis contains the same amount or potency of CBD and THC. For instance, Indica-dominant strains of cannabis contain higher CBD content than the Sativa variant, in which THC content is relatively more than the CBD. Therefore, gaining access to the right plant strain is a must for the pharmaceutical community if they are to offer the right therapeutic effect to patients.
With its many years of experience and know-how in cannabis cultivation, Nedcann aims to make medical cannabis easily accessible for the pharmaceutical fraternity. “We are presently working with different European pharmaceutical companies especially in Germany and also in other countries, and leading the charge for the production and usage of medical cannabis products in those regions,” says Stephan van Gerven, CEO of Nedcann. To this end, Nedcann leverages state-of-the-art equipment, techniques and superior quality materials to cultivate medical cannabis of the best quality at its solely indoor cultivation facilities.
Such an approach gives Nedcann total control over the production process to maintain the necessary quality of the cannabis plants required for the pharmaceutical industry.
Unleashing the Benefits of Medical Cannabis
Nedcann has created numerous small and medium-sized growing rooms with absolute controlled monitoring and optimal combinations of fertiliser, temperature, humidity, light, water, and CO2 using different sensors and software— to optimise medical cannabis production. The company has built several test rooms as well to continuously experiment with appropriate components to initiate different enzymatic processes in the medical cannabis plants. Once the plants’ flowers reach optimum growth, they are then cut, trimmed, dried slowly upside down for up to 14 days, and packed in a dedicated German EU GMP certified 2200m2 cleanroom, and are only then delivered to clients as dried cannabis flowers. It must be noted that each growing room’s harvest is separately dried in one of the 14 certified drying rooms. “We can, therefore, mitigate any chance of cross-contamination of cannabis buds,” says van Gerven.
Nedcann also pays special attention to detail in its internal quality and standard operating procedures, which the company tags as the “Nedcann Standard,” reflecting its consistently high quality. “Adjacently, we also offer our clients viewing access to the growing and drying room via CCTV cameras, so that they can always monitor the growth of “their plants,” shares van Gerven. As can be understood, Nedcann produces medical cannabis following the requirements for global Good Agricultural Practices (GAP) certification. In terms of packaging, the company strictly follows the Good Manufacturing Practice (GMP) and EU-GMP guidelines. The company is also presently working on obtaining the German certification.
With its many years of experience and know-how in cannabis cultivation, Nedcann aims to make medical cannabis easily accessible for the pharmaceutical fraternity
For clients who look for particular strains of medical cannabis with specific levels of CBD and THC, Nedcann has the necessary expertise to produce cloned plants from gene pools with characteristics prescribed by clients. Using clones instead of seeds ensures that clients achieve exactly the same results in growing as the mother plant (CBD, THC, Terpenes, etc.). Additionally, the clones offered by Nedcann can easily be traced back to the initial tissue culture. These clones also sport identification passports that address specific requirements of growers worldwide. As a result, the clients rest assured that all the cannabis plants if optimally grown following Nedcann guidelines, will end up with the same characteristics they expect.
Nedcann is an honorary member of the Legal Cannabis Coalition (LCC) of Holland whose members support the latest cultivation techniques that the Top Dutch Horticulture Sector has to offer. “Also, in the future, we plan to offer medical cannabis oil extracts using CO2 extraction and our existing equipment while staying true to Nedcann Standards,” shares van Gerven. Alongside the medical products, Nedcann is also planning to add medical cannabis by-products. Nedcann is looking at the bright future ahead, in Europe and other parts of the world as well. “And drawing from our knowledge, experience, and commitment to the highest quality, we truly want to be the number one in medical cannabis production and guarantee our customers a steady supply of consistent, superior quality products all-year-round without compromises,” concludes van Gerven.